Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$2,573 Mln
P/E Ratio
--
P/B Ratio
7.3
Industry P/E
--
Debt to Equity
0
ROE
-0.74 %
ROCE
--
Div. Yield
0 %
Book Value
--
EPS
-2.65
CFO
$-559.31 Mln
EBITDA
$-527.71 Mln
Net Profit
$-678.25 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Immunovant Inc (IMVT)
| -41.34 | -26.02 | -37.45 | -49.44 | 45.27 | -4.43 | -- |
|
BSE Sensex
| 2.39 | 4.18 | 4.86 | 8.78 | 11.89 | 20.62 | 11.13 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
|
|---|---|---|---|---|---|
|
Immunovant Inc (IMVT)
| -40.95 | 137.35 | 108.33 | -81.55 | 191.05 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.73 | 9,808.03 | 20.22 | 23.13 | |
| 284.42 | 8,956.09 | 22.08 | 58.42 | |
| 26.83 | 9,559.25 | -- | -28.77 | |
| 103.38 | 10,030.35 | 30.81 | 14.16 |
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. The company develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment... crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, Graves diseases, and warm autoimmune hemolytic anemia. Immunovant, Inc. is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd. Address: 320 West 37th Street, New York, NY, United States, 10018 Read more
Executive Chairperson of the Board
Dr. Frank M. Torti M.B.A., M.D.
Executive Chairperson of the Board
Dr. Frank M. Torti M.B.A., M.D.
Headquarters
New York, NY
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Immunovant Inc (IMVT) stood at $ 489 Mln as on 31-Dec-24
The share price of Immunovant Inc (IMVT) is $14.53 (NASDAQ) as of 23-Apr-2025 14:40 EDT. Immunovant Inc (IMVT) has given a return of 45.27% in the last 3 years.
Immunovant Inc (IMVT) has a market capitalisation of $ 2,573 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Immunovant Inc (IMVT) is 7.30 times as on 22-Apr-2025, a 232% premium to its peers’ median range of 2.20 times.
Since, TTM earnings of Immunovant Inc (IMVT) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Immunovant Inc (IMVT) and enter the required number of quantities and click on buy to purchase the shares of Immunovant Inc (IMVT).
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. The company develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, Graves diseases, and warm autoimmune hemolytic anemia. Immunovant, Inc. is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd. Address: 320 West 37th Street, New York, NY, United States, 10018
The CEO & director of Dr. Frank M. Torti M.B.A., M.D.. is Immunovant Inc (IMVT), and CFO & Sr. VP is Dr. Frank M. Torti M.B.A., M.D..
There is no promoter pledging in Immunovant Inc (IMVT).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Immunovant Inc (IMVT) | Ratios |
|---|---|
|
Return on equity(%)
|
-85.3
|
|
Operating margin(%)
|
-27013.67
|
|
Net Margin(%)
|
-25514
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Immunovant Inc (IMVT) was $0 Mln.
$0.28
(
